MILWAUKEE, Sept. 1, 2022 /PRNewswire/ -- Ademi LLP is investigating Forma Therapeutics (NASDAQ: FMTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk.
Click here to learn how to join the action: https://www.ademilaw.com/case/forma-therapeutics-holdings-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Ademi LLP alleges Forma Therapeutics' financial outlook and prospects are excellent and yet Forma Therapeutics holders will receive only $20 per share. The transaction agreement unreasonably limits competing bids for Forma Therapeutics by imposing a significant penalty if Forma Therapeutics accepts a superior bid. Forma Therapeutics insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Forma Therapeutics' board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Forma Therapeutics.
If you own Forma Therapeutics common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/forma-therapeutics-holdings-inc
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article